Van ECK Associates Corp Has $237.67 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Van ECK Associates Corp trimmed its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 44.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 723,471 shares of the medical research company's stock after selling 580,281 shares during the period. Van ECK Associates Corp owned approximately 2.58% of Bio-Rad Laboratories worth $237,667,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BIO. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Bio-Rad Laboratories by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company's stock valued at $147,583,000 after buying an additional 4,260 shares during the period. Westfield Capital Management Co. LP lifted its holdings in Bio-Rad Laboratories by 3.9% in the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company's stock valued at $84,571,000 after buying an additional 9,584 shares during the period. Point72 Asset Management L.P. acquired a new position in Bio-Rad Laboratories in the third quarter valued at approximately $83,681,000. Mawer Investment Management Ltd. lifted its holdings in Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock valued at $72,900,000 after buying an additional 84,237 shares during the period. Finally, Wedge Capital Management L L P NC acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at approximately $28,740,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Down 9.7 %

Shares of BIO stock traded down $29.81 during trading hours on Friday, hitting $276.55. 1,065,491 shares of the company were exchanged, compared to its average volume of 151,421. The business has a 50 day moving average of $338.72 and a two-hundred day moving average of $336.15. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. As a group, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.33 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BIO shares. Wells Fargo & Company cut their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a report on Wednesday. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Citigroup increased their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.